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Recently  we investigated  the heavy  metal  hazards  of  Nigerian  smokeless  tobacco  products  ‘STP’.  Since
‘STPs’  are  advocated  as safer  alternatives  to  cigarets,  the public  health  implication  should  be  ascertained.
This  is  a risk  assessment  of poly  aromatic  hydrocarbons  ‘PAHs’  in  ‘STPs’  used  in Nigeria.
Thirty  ‘STPs’  from  different  parts  (South  East,  South  West,  Niger  Delta  and North  Central)  of  Nigeria
were  studied.  The  15 PAHs  were  assayed  using  gas  chromatographic  system  (6890  series  and  6890
plus)  equipped  with  a quadrupole  Mass  Spectrometer  (Agilent  5975  MSD)  after  ultrasonic  extraction
of  the  ‘STPs’  and clean up of  the  extract.  Toxicity  equivalent  of  benzo[a]pyrene  concentration(g/kg) in
‘STPs’were  determined.  The  daily  exposure  and  the cancer  risk  associated  with  exposure  to STP  were
calculated.
Sample A1  (south  east)  had  the highest  concentration  of  PAH  225.84  g/kg,  while  sampleA3  (North
central)  had  the  least  PAH  concentration  of 1.09  g/kg.  ‘STPs’  from  South  East  showed  highest  levels  of
PAHs.  The  total  B[a]P  TEQ  of the  ‘STPs’  from  the  South  East  ranged  from  0.24  to  29.23, South  West  ranged
from  0.94  to  14.55,  Niger  Delta  ranged  from  2.28  to  22.88,  and North  Central  ranged  from  0.11  to  9.47.
The  calculated  risk  estimates  for ‘STPs’  from  the  South  East  ranged  from  5.43  E-05  to 4.50  E-07,  South
West  2.70  E-05  to  1.74  E-06,  Niger Delta  4.30  E-05  to 4.20  E-06,  and  North  Central  1.75 E-05  to 2.08  E0-7.
Although  the  calculated  risk  estimates  seem  to be within  or  below  the  the  U.S.  EPA  cancer  risk  range
of  1 × 10−4–1 × 10−6, the  total  B[a]P  TEQ  of  the  STPs  suggest  a more  indepth  risk  assessment  in animal
model  to ascertain  the  safety  of PAHs  in  Nigerian  ‘STPs’.
©  2015  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Investigation of harmful agents contained in smokeless tobacco
s an important step toward the reduction of its adverse public
ealth effects in man. In 2012, the US Food and Drug Administra-
ion (FDA) established a list of 93 “harmful and potentially harmful
onstituents” (HPHCs) for tobacco products [12]. The smokeless
obacco products ‘STPs’ include a variety of tobacco products
ntended for oral or nasal use. The International Agency for Research
n Cancer (IARC) lists 28 carcinogens present in smokeless tobacco
18]. Oral smokeless tobacco use can lead to precancerous oral
esions and other forms of cancer like oral and pancreatic cancer
18]. Smokeless tobacco is also associated with an increased risk
f esophageal cance [5]. In Nigeria, smokeless tobacco is available
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in dried, cured, and natural forms. In addition to smoking, it can
be placed between the cheek and gum (dipped), or sniffed into the
nose as ﬁnely powdered snuff.
The poly aromatic hydrocarbons (PAHs) are a large group of
organic compounds containing two  or more aromatic rings [15]
and diverse group of carcinogens arising from the incomplete com-
bustion of organic materials including tobacco. The most potent
PAH carcinogens are benzo[a]anthracene, benzo[a]pyrene, and
dibenz[a,h]anthracene [8].
Nasal snuff inhalation has been reported to be associated with
nasal sinus and nasopharyngeal cancer in some parts of Africa
[13]. Smokeless tobacco is used in many parts of Nigeria for var-
ious reasons such as pleasure, in treating symptoms like nasal
congestion, cough, cold, etc., and as tradition in social gatherings
in various quantities without the knowledge of its health effects.
Recently, there has been advocacy for the use of smokeless tobacco
use in many countries including Nigeria as a safer alternative to
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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igaret smoking. This promotion may  heighten the use of smokeless
obacco.
Unlike some developed countries most smokeless tobacco prod-
cts ‘STPs’ in Nigeria are not manufactured using the pasteurized
obacco which is claimed to pose a signiﬁcantly lower risk of cancer
ut by ﬁre-cured tobacco, among other technologies. Toxicological
isk assessment principles have been applied to tobacco products
14]. The information obtained from such a risk assessment has
ecently been used to propose reductions in toxicants in tobacco
roducts to the regulatory authorities [7]. This study therefore
pplies a risk assessment methodology developed by some reg-
latory bodies like the Agency for Toxic Substances and Disease
egistry and US Environmental Protection Agency (USEPA) to esti-
ate the cancer risk associated with exposure to most commonly
sed ‘STP’ in different parts of Nigeria since at the moment there
re no regulations of ‘STPs’ in Nigeria. The results of this study are
ntended to form the basis for scientiﬁc discussion on an appropri-
te regulatory approach for ‘STPs’ [10].
. Materials and methods
Using a market basket protocol thirty brands of smokeless
obacco (dry snuff) purchased in August 2012 from different parts
f Nigeria (South East, South West, Niger Delta and North Central)
ere used in the study. The tobacco used in the present study was
re-cured, fermented, and subsequently processed into a dry, pow-
ered form with less than 10% moisture content packaged and sold
n small metal containers.
Glass wares were washed thoroughly with hot detergent solu-
ion followed by rinsing with puriﬁed water and acetone (analytical
rade) respectively. These were ﬁnally baked in the oven at 100 ◦C
vernight. To avoid contaminations of smokeless tobacco samples,
ifferent glass wares and syringes were used for standards and for
olutions extracted from samples.
Extraction of poly aromatic hydrocarbons from the smoke-
ess tobacco samples was done with a sonicator (Ultrasonic
ath-Elmsonic S40H) in accordance with US SW-846 Method
550. Two grams of each of the smokeless tobacco samples
as extracted with a 50:50 mixture of acetone and methylene
hloride spiked with 1 ml  of PAH internal standard and shaken
horoughly for proper mixing before placing in an ultrasonic
ath. The concentrations of 16 PAH (naphthalene, acenaphtylene,
cenaphtene, ﬂuorene, phenanthrene, anthracene, ﬂuoranthene,
yrene, benzo[a]anthracene, chrysene, benzo[b]ﬂuoranthene,
enzo[k]ﬂuoranthene, benzo[a]pyrene, indeno[1,2,3-c,d]pyrene,
ibenzo[a,h]anthracene, and benzo[g,h,i]perylene) were analyzed
y gas chromatography (gas chromatograph (GC-FID)) with GC
ecorder interfaced with a HP.
The EPA-16 PAHs determination was conducted at Jaros Inspec-
ion Services Ltd., Port Harcourt, Rivers State, Nigeria using Gas
hromatographic System (6890 series and 6890 plus) equipped
ith a dual detector (FID-ECD), dual column and TriPlus AS
uto-sampler with helium carrier gas and a quadrupole Mass Spec-
rometer (Agilent 5975 MSD) based on USEPA method 8100 [10].
 2.00 l of extracts were injected into the GC port set at col-
mn  conditions: HP-5 crosslinked PH-ME siloxane, length of 30 m,
.D: 0.25 mm,  thickness of 1 m with helium carrier gas set in
he spitless, constant ﬂow mode with 1.2 ml/min ﬂow rate. Other
C–MS operating set-up were done according to the instrument’s
ethod development as speciﬁed in the operating instruction man-
al. Identiﬁcation and quantiﬁcation of individual PAHs was based
n internal calibration standard containing known concentrations
f the 16 PAHs (EPA-16). The speciﬁcity of the 16 PAHs sought for
n the samples was conﬁrmed by the presence of transition ions
quantiﬁer and qualiﬁer) as shown by their retention times whicheports 2 (2015) 1019–1023
corresponded to those of their respective standards. The measured
peak area ratios of precursor to quantiﬁer ion were in close agree-
ment with those of the standards.
The detection limit (LOD), estimated as three times the back-
ground noise (IUPAC criterion), was similar for all analyzed
compounds and results were less than 0.015 g/kg dw for all ana-
lytes. The blank values of analytical procedure remained always
below the quantiﬁcation limit (LOQ): 0.05 g/kg dw, estimated as
10 times.
The potential for cancer effects was  consequently estimated
by calculating the incremental probability that an individual will
develop cancer over a lifetime as a result of chronic exposure to a
particular substance (that is, above baseline lifetime risk). Recog-
nizing differences in the route of administration between cigarette
(inhalation) and STP constituents (oral absorption or ingestion),
the equation used for estimating cancer risk has been adapted as
follows [4]:
The cancer potency factor (CPF) is the lifetime cancer risk esti-
mated to result from continuous exposure to a substance at a
concentration of 1 mg/kg body weight. The lifetime average daily
exposure (ADE) is estimated by adjusting the ADE according to
adult body weight (assumed to be 70 kg), the number of years of
STP use (assumed to be 30 years) and the average lifetime (assumed
to be 70 years).
The equation for estimating the lifetime ADE  is the following:
Incrementallifetimecancerrisk = ADElifetime × CPF
ADElifetime =
ADE × Number of years snufﬁng
Average lifetime
where ADElifetime = lifetime average daily inhalational expo-
sure (mg/kg body weight/day) and CPF = cancer potency factor
((mg/kg body weight/day)−1). ADE = average daily exposure,
CPF = cancer potency factor also called CSF “Cancer Slope Fac-
tor”(mg/kg/day) − 1; 6.1 (mg/kg/day) − 1 for B(a)P [10], number
of years snufﬁng = assumed to be 30 years, and average life-
time = 70 years [4].
As with the assumptions used in previously published assess-
ments for tobacco products [14,22] the above equation is based
on the assumption that 100% of the toxicant is transferred and is
thus potentially biologically available, as would be typical for any
conservative risk assessment calculation.
2.1. Toxic equivalent B[a]P concentration
The concentrations of carcinogenic PAHs, expressed as B[a]P
equivalent were calculated using the model developed by [6]
TEQ =
∑
(PAHi × TEFi)
TEQ = toxicity equivalent of a mixture, TEFi = toxic equivalency fac-
tor, i.e., relative potency (as based on carcinogenicity) to benzo(a)
pyrene, PAHi = concentration of PAH congener i, and TEFi = toxic
equivalent.
2.2. Daily Exposure
Due to the health risk associated with exposure to carcinogenic
PAH, in the present study the average daily exposure based on the
use of STP was  calculated by a modiﬁcation of the equation ATSDR
[1].Dose =
Concentratrion × Intake Rate
×Exposure Factor × Conversion Factor
Body weight
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Table  1
PAH concentration (g/kg) in smokeless tobacco products.
Nap Ac An Ace Fl Phe Flt Py B[a]A Chry B[b,k]F B[a]P I[cd]P B[ah]A  B[ghi]P
∑
PAH
South East
A1 40.9 ND 38.0 13.0 5.92 8.15 29.17 15.6 6.96 11.8 17.4 5.62 13.62 19.69 ND 225.84
A2  2.87 3.02 ND ND ND ND ND ND ND ND ND ND ND 4.01 12.0 21.9
A4  ND 0.01 ND ND ND ND ND ND 17.0 8.01 12.04 ND ND ND ND 37.06
A8  ND ND ND ND ND ND ND ND ND 2.26 1.99 ND ND 2.44 9.91 16.6
A9  3.27 ND ND ND ND ND ND 2.75 ND ND 1.01 ND 1.04 1.01 1.02 10.1
A12  ND ND 7.23 ND ND ND 3.17 ND ND 6.28 5.54 2.27 ND ND ND 24.49
A13  ND ND ND ND ND ND 3.15 ND 1.71 4.54 7.50 ND ND ND 6.17 23.07
A14  ND ND ND ND ND ND ND 6.13 15.2 ND 17.0 5.10 15.0 13.1 15.0 86.53
A18  ND ND ND ND 6.15 ND 4.97 2.17 5.68 4.59 6.06 1.91 5.59 4.61 4.49 46.22
A19  ND ND ND ND 1.72 ND 90.54 ND 0.54 2.02 7.88 0.45 3.98 2.60 1.57 111.3
A20  ND ND ND ND 15.6 ND 7.31 ND 15.23 2.42 7.54 5.91 4.74 1.23 1.22 61.2
A22  ND ND ND ND 2.68 ND 1.21 ND 6.31 2.88 11.63 4.21 7.20 3.73 9.70 49.55
A25  ND 5.45 6.60 ND 0.86 5.86 7.27 0.22 3.18 ND 3.16 ND 4.21 4.43 ND 41.24
A27  ND ND 0.58 ND ND ND 5.71 0.13 ND 7.66 1.48 ND ND 0.01 ND 15.5
A28  1.56 ND 1.09 ND ND 5.70 0.83 0.76 0.50 6.40 7.42 0.99 1.45 1.17 1.17 29.04
A29  ND ND 6.57 ND ND 5.87 0.03 1.65 1.65 0.33 0.71 0.94 2.31 2.77 2.71 25.54
A30  1.99 3.23 22.1 4.06 9.76 12.18 1.17 5.29 0.62 11.68 9.32 9.61 4.10 6.98 ND 102.09
South  West
A5 ND ND ND ND ND ND 0.41 ND ND 1.38 4.12 0.68 ND ND 1.87 8.46
A7  ND ND 4.16 ND ND ND 1.93 ND ND 5.52 0.41 3.96 ND ND 5.33 21.31
A10  ND 2.68 ND ND ND ND ND ND ND 6.29 ND ND 2.27 0.65 1.95 13.84
A11  4.87 ND ND ND ND ND ND ND ND ND 0.03 5.13 ND ND 0.01 10.04
A21  ND ND ND ND 2.65 ND 9.53 ND ND 3.74 1.5 9.88 5.68 3.91 3.64 40.53
A23  ND ND ND ND ND ND 0.1 3.01 ND 9.1 ND 9.1 ND 2.01 0.1 23.42
South  South
A15 0.87 ND ND ND ND ND ND ND ND 0.12 1.03 4.32 ND ND 0.01 6.35
A16  ND ND ND ND ND ND 1.18 ND 2.47 4.27 2.81 0.73 9.79 ND 8.22 29.47
A17  ND ND ND ND 3.98 ND 21.42 ND ND ND 2.05 ND ND 27.67 3.11 58.23
A24  ND ND ND ND 1.43 ND 2.55 ND 5.24 2.52 3.29 1.64 9.16 2.77 2.40 31.0
A26  ND ND 0.24 ND 5.76 5.75 ND 8.77 0.92 0.84 2.53 9.35 2.33 6.37 0.02 42.88
North  Central
A3 ND 0.024 ND ND ND ND ND ND ND ND ND ND 1.02 0.01 0.031 1.09
A6  ND ND ND ND 2.23 ND 4.32 ND ND 2.42 ND 7.40 1.68 1.99 8.51 28.60
AC = acenaphthylene, Ace = acenaphthene, Fl = ﬂourene, Phe = phenanthrene, An = anthracene, Flt = ﬂouranthene, Py = pyrene, B[a]A = benzo[a]anthracene, Chry = chrysene,
B[bk]F  = benzo[b,k]ﬂouranthene, B[a]P = benzo[a]pyrene, D[a,h]A = dibenzo[a,h]anthracene, B[ghi]P = benzo[ghi]pyrelene, and I[cd]P = indenol[cd-123]pyrelene.
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Wose = estimated exposure dose (mg/kg/day), concentra-
ion = contaminant concentration (mg/kg), intake rate = intake rate
f STP (assuming 10 pouches per day, 1 g/pouch) 50 g [21], expo-
ure factor = exposure factor (6 times a week per year = 312/365
nitless), conversion factor = conversion factor (10−6 kg/mg), and
ody weight = body weight (assumed to be 60 kg).
. Results
The result for the PAH content of the STPs are shown in Table 1.
he STPs are ordered by different regions within the country from
hich they were collected. All the 30 samples of STPs analyzed had
arying degrees of PAH contamination. No sample from the four
egions contained all the 15 individual PAHs measured. Sample A1
South East) had the highest concentration of total PAH contamina-
ion of 225.84 g/kg, while sampleA3 (North Central) had the least
otal PAH concentration of 1.09 g/kg. STP samples collected from
outh East showed higher levels of total PAH contamination than
he samples from other regions. The highest concentration across
he four different regions occurred in A1(South East), A21(South
est), A17(South South), and A6(North Central) with 225.84, 40.53,
8.23, and 28.6 g/kg, respectively (Table 1).
The toxicity equivalent (TEQ) of benzo[a]pyreneoncentration(g/kg) in smokeless tobacco product from dif-
erent regions of Nigeria is shown on Table 2. The total B[a]P TEQ
f the STP from the South East ranged from 0.24 to 29.23, South
est ranged from 0.94 to 14.55, Niger Delta ranged from 2.28 to22.88 and North Central ranged from 0.11 to 9.47. STP A30 has the
highest B[a]P concentration from the South East of 9.61, whereas
the B[a]P concentrations from South West, Niger Delta and North
Central were 9.88, 9.35 and 7.4, respectively Table 2.
Table 3 shows the daily exposure concentrations to carcinogenic
PAHs in smokeless tobacco products from different parts of Nigeria.
Based on the result of the analysis, the cancer risk associated with
exposure to STP was calculated and presented in Table 4. The cal-
culated risk estimates for STP from the South East ranged from 4.50
E-07 to 5.43 E-05, South West 1.74 E-06 to 2.70 E-05, South South
4.20 E-06 to 4.30 E-05, and North Central 2.08 E-07 to 1.75 E-05.
4. Discussion
In this study, we have quantiﬁed the levels of 15 PAHs and
carried out a detailed risk assessment of a wide range of smoke-
less tobaccos used in Nigeria. The present study may  be one of
the most extensive surveys of PAHs in STPs published to date
from sub Sahara Africa. The PAHs marked as carcinogenic by
the Scientiﬁc Committee on Food (SCF), for which further inves-
tigation of the relative levels in consumables is required are:
benz[a]anthracene, benzo[b]ﬂuoranthene, benzo[k]ﬂuoranthene,
benzo[j]ﬂuoranthene, benzo[g,h,i]perylene, benzo[a]pyrene
chrysene,cyclopenta[c,d]pyrene, dibenz[a,h]anthracene,
dibenzo[a,e]-pyrene, dibenzo[a,i]pyrene, dibenzo[a,l]pyrene,
indeno[1,2,3-cd]pyrene, 5 benzo[j]ﬂuoranthene,
cyclopenta[c,d]pyrene, 5-methylchrysene [11] This study has
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Table 2
Toxicity equivalent quotient (TEQ) of benzo[a]pyrene concentration(g/kg) in smokeless tobacco product carcinogenic PAHs.
B[a]P B[a]A B[b + k]F CHRY D[a,h]A I[c,d]P Total B[a]P TEQ
TEF 1 0.1 0.1 0.01 1 0.1
South East
A1 5.62 0.69 1.74 0.12 19.69 1.36 29.23
A2  ND ND ND ND 4.01 ND 4.01
A4  ND 1.7 1.2 0.08 ND ND 2.98
A8  ND ND 0.19 0.02 2.44 ND 2.65
A9  ND ND 0.1 ND 1.01 0.1 1.21
A12  2.27 ND 0.55 0.063 ND ND 2.88
A13  ND 0.17 0.75 0.05 ND ND 0.97
A14  5.10 1.52 1.7 ND 13.1 1.5 22.92
A18  1.91 0.57 0.6 0.05 4.61 0.56 8.92
A19  0.45 0.054 0.79 0.02 2.6 0.39 4.30
A20  5.91 1.52 0.75 0.02 1.23 0.47 9.90
A22  4.21 0.63 1.16 0.03 3.73 0.72 10.48
A25  ND 0.32 0.32 ND 4.43 0.42 5.49
A27  ND ND 0.15 0.08 0.01 ND 0.24
A28  0.99 0.05 0.74 0.06 1.17 0.15 3.16
A29  0.94 0.17 0.07 0.003 2.77 0.23 4.18
A30  9.61 0.06 0.93 0.12 6.98 0.41 18.11
South West
A5 0.68 ND 0.41 0.014 ND ND 1.11
A7  3.96 ND 0.04 0.052 ND ND 4.05
A10  ND ND ND 0.063 0.65 0.23 0.94
A11  5.13 ND 0.003 ND ND ND 5.13
A21  9.88 ND 0.15 0.037 3.91 0.57 14.55
A23  9.1 ND ND 0.09 2.01 ND 11.2
South South
A15 4.32 ND 0.10 0.001 ND ND 4.42
A16  0.73 0.25 0.28 0.043 ND 0.98 2.28
A17  ND ND 0.21 ND 22.67 ND 22.88
A24  1.64 0.52 0.33 0.003 2.77 0.92 6.18
A26  9.35 0.01 0.25 0.008 6.37 0.23 16.3
North Central
A3 ND ND ND ND 0.01 0.102 0.11
0
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EF: PAHs toxic equivalency factor with respect to B[a]P (Nisbet and LaGoy, 1992).
hown measurable levels of some of these PAHs. Some PAHs are
oth carcinogenic and mutagenic. It is however feared that, these
ategory of PAHs that have not been found to be carcinogenic
ay  be active as synergists that increase the carcinogenicity of
ther PAHs [19]. Human exposure to single PAHs does not occur
ince PAHs are always encountered as complex mixtures. This
eculiarity of exposure to complex mixture of varying composition
onstitute the challenge in human risk assessment.
Although not all PAHs are considered carcinogenic (e.g., pyrene),
he U.S. EPA has conﬁrmed that the following benz(a) anthracene,
enzo(a) pyrene, benzo(b) ﬂuoranthene, benzo(k) ﬂuoranthene,
hrysene, dibenz(a,h) anthracene, and indeno(1,2,3-c,d)  pyrene are
robable human carcinogens [2]. Similarly the National Toxicology
rogram (NTP) of the United States Public Health Service opined
hat 15 individual PAHs to be “reasonably anticipated to be human
arcinogens”[20]. Also the International Agency for Research on
ancer (IARC) upgraded its overall evaluation of benzo(a) pyrene
o Group 1 (carcinogenic to humans) in 2010 [17]. B[a]P pres-
nce in smokeless tobaccos has been a focus of concern in public
ealth as a result of some recent surveys [24,26]. A single PAH (e.g.,
enzo[a]-pyrene) may  not always be used as a surrogate for all
AHs in drawing conclusions for the other PAHs, especially those
ith only two or three aromatic rings [9]. Benzo[a]pyrene is just
nly one of many carcinogenic PAHs in smokeless tobacco. More-
ver, some PAHs act as promoters for the carcinogenicity of other
AHs, without necessarily being carcinogenic themselves [16]. A
ore accurate risk assessment of other PAHs in smokeless tobacco
ill help evaluate the potential public health concerns in users
f smokeless tobacco. Although benzo[a]pyrene can and has been.002 1.99 0.17 9.47
used as a broad marker for overall PAH content, more accurate
evaluations can be obtained with expanded analysis for each of
the individual PAHs [9]. Notwithstanding, STP samples from vari-
ous part of Nigeria contain worrisome levels of B[a]P. The cancer
potency in the samples varied substantially and the concentra-
tions ranges from 0.11 to 29.23 g/kg. The high TEQ value observed
in sample A1 may  be due to the high total individual PAH con-
centration. Sample A3 which has the lowest B[a]P equivalent was
observed to have only few individual carcinogenic PAH contribut-
ing to the total PAH concentration. The varying concentrations of
B[a]P equivalent is due to the carcinogenic PAH contribution to
total PAH concentration. Fire curing of tobacco may  explain the
high levels of BaP (a product of combustion) in some of the STPs
[23,25]. The present study suggests that BaP concentrations of some
of the STP were at levels that do meet the criteria for an ‘accept-
able’ cancer risk. BaP is an avoidable constituent of STPs, therefore it
should be eliminated starting with an enforceable regulatory limit
as suggested by the WHO’s tobacco regulation study group [27].
The maximum value from the South East is 5.43 E-05, but
remained within the range advocated by USEPA (E-06–E-04). The
maximum value of cancer risk calculated for south west, south
south and North Central all fell within the USEPA risk limit. The
minimum risk limit of South East and North Central (4.50 E-07 and
2.08 E0-7) were either within or below the benchmark for accept-
able risk by USEPA. Excess cancer risk is expressed as a portion of the
population that may  be affected by a carcinogen during a lifetime of
exposure. An estimated risk of 1 × 10−6 predicts the probability of
one additional cancer, over background, in an exposed population
of one million. The estimated cancer risk from exposure to PAHs
O.E. Orisakwe et al. / Toxicology R
Table  3
Daily exposure concentration to carcinogenic PAH from smokeless tobacco products.
Samples Exposure dose (mg/kg)
South East
A1 2.08 E-05
A2 2.86 E-06
A4 2.12 E-06
A8 1.89 E-06
A9 8.62 E-07
A12 2.05 E-06
A13 6.91 E-07
A14 1.63 E-05
A18 5.90 E-06
A19 3.06 E-06
A20 7.05 E-06
A22 7.46 E-06
A25 3.91 E-06
A27 1.71 E-07
A28 2.25 E-06
A29 2.98 E-06
A30 1.29 E-05
South West
A5 7.84 E-07
A7 2.92 E-06
A10 6.69 E-07
A11 3.65 E-06
A21 1.04 E-05
A23 7.98 E-06
South South
A15 3.15 E-06
A16 1.62 E-06
A17 1.63 E-05
A24 4.40 E-06
A26 1.14 E-05
North Central
A3 7.84 E-08
A6 6.75 E-06
Table 4
Cancer risk resulting from exposure to smokeless tobacco products in Nigeria.
Range South East South West Niger Delta North Central
Max  5.43 E-05 2.70 E-05 4.30 E-05 1.75 E-05
Min  4.50 E-07 1.74 E-06 4.20 E-06 2.08 E0-7
a
U
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i
e
‘
b
m
t
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l
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[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[Mean 1.40 E-05 1.14 E-05 1.93 E-05 8.90 E-06
rising from use of STP were calculated to be within or below the
.S. EPA cancer risk range of 1 × 10−4–1 × 10−6 [3].
.1. Study limitations
The limited number of ‘STPs’ and ‘STP’ constituents included
n the calculations in this investigation is considered conservative
stimates of actual cancer risk. The true bioavailability of PAHs in
STPs’ may  have been underestimated or overestimated, given that
ioavailability may  differ by compound and that, over time, users
ay  increase the intensity of use and correspondingly increase
heir exposure to these constituents.
. ConclusionsThe total B[a]P TEQ of the STPs in this study is of public health
oncern. Although this study suggests the safety of many smoke-
ess tobaccos in the Nigerian market, we recommend that further
ndepth risk assessments of these smokeless tobaccos in vivo.
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